US4508710A
Expired / Lapsed
US
⏱️ 0.0 years remaining
In vitro and in vivo treatment of cancer cells and treatment of viruses with a tripeptide compound
Assignee: Proter SpA
•
Filing: 1983-02-23
•
Granted: 1985-04-02
•
Expires: 2003-02-23
Abstract
Abstract The cancericidal activity of all the permutations of a tripeptide compound formed from dichlorodiethylaminophenylalanine, parafluorophenylalanine and methionine bonded together with peptide links was demonstrated using seven in vitro tumor cell lines. The viabilities of each of the tumor cell lines were significantly reduced by treatment for 1 to 24 hours with 1 to 50 μg of the tripeptide per ml of carrier solvent. A pulse exposure to the tripeptide demonstrated that the reductions in tumor cell was comparable to continuous exposure. Other in vitro tests were all conducted on AKR mice. Methods of treating virus by exposing the virus to one of the noted tripeptide compounds is also contemplated. Methods of treating tumor cells with the tripeptides dissolved in a solvent consisting of dimethylacetamide, propylene glycol and absolute ethanol are also contemplated by the present invention.
Inventors
- 👤 Augusto DeBarbieri
- 👤 Julius G. Bekesi
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-11-09 04:01
CPC Classifications
C; C07; C07H; C07H13/00; C07H13/02; C07H13/04; C07H15/00; C07H15/02; C07H15/04; C07K; C07K5/00; C07K5/04; C07K5/06; C07K5/06008; C07K5/06078; C07K5/08; C07K5/0802; C07K5/0812; C07K5/0827
Claims Analysis
Total Claims: 20
Claim 1
Independent Claim
49 words
A method of controlling human and animal tumor cells transplanted into a living animal comprising injecting the animal with a therapeutically effective amount of a tripeptide compound, said tripeptide has members selected from a group consisting of: (1) 3-(p-fluorophenyl)-L-alanyl-3-[m-bis(2-chloroethyl)-aminophenyl]-L-alanyl-L-methionine (2) 3-[m-bis(2-chloroethyl)aminophenyl]-L-alanyl-3-(p-fluorophenyl)-L-alanyl-L-methionine (3) 3-(p-fluorophenyl)-L-alanyl-L-methionyl-3-[m-bis(2-chloroethyl)aminophenyl]-L-alanine (4) 3-[m-bis(2-chloroethyl)aminophenyl]-L-alanyl-L-methionyl-3-(p-fluorophenyl)-L-alanine (5) L-methionyl-3-(p-fluorophenyl)-L-alanyl-3-[m-bis(2-chloroethyl)aminophenyl]-L-alanine (6) L-methionyl-3-[m-bis(2-chloroethyl)aminophenyl]-L-alanyl-3-(p-fluorophenyl)-L-alanine.
Claim 2
Independent Claim
49 words
A method of controlling human and animal tumor cells transplanted into a living animal comprising injecting the animal with a therapeutically effective amount of a tripeptide compound, said tripeptide has members selected from a group consisting of: (1) 3-(p-fluorophenyl)-L-alanyl-3-[m-bis(2-chloroethyl)-aminophenyl]-L-alanyl-L-methionine (2) 3-[m-bis(2-chloroethyl)aminophenyl]-L-alanyl-3-(p-fluorophenyl)-L-alanyl-L-methionine (3) 3-(p-fluorophenyl)-L-alanyl-L-methionyl-3-[m-bis(2-chloroethyl)aminophenyl]-L-alanine (4) 3-[m-bis(2-chloroethyl)aminophenyl]-L-alanyl-L-methionyl-3-(p-fluorophenyl)-L-alanine (5) L-methionyl-3-(p-fluorophenyl)-L-alanyl-3-[m-bis(2-chloroethyl)aminophenyl]-L-alanine (6) L-methionyl-3-[m-bis(2-chloroethyl)aminophenyl]-L-alanyl-3-(p-fluorophenyl)-L-alanine.
Claim 3
Dependent Claim
20 words
A method of controlling tumor cells as claimed in claim 1, wherein the tripeptide compound is 3-(p-fluorophenyl)-L-alanyl-3-[m-bis(2-chloroethyl)-aminophenyl]-L-alanyl-L-methionine ethyl ester hydrochloride.
Claim 4
Dependent Claim
50 words
The method of claim 2, wherein a carrier solution is prepared by first dissolving 10 mg of the tripeptide in a solution of 0.25 ml of N,N-dimethylacetamide, 0.25 ml of pure ethanol, and 0.5 ml of propylene glycol; and then further diluting with an aqueous solution of 50% propylene glycol.
Claim 5
Dependent Claim
32 words
The method of claim 2, wherein the tumor cells are controlled with a single therapeutically effective dose between about 10 to about 20 mg of the tripeptide per kg of subject weight.
Claim 6
Dependent Claim
23 words
The method of claim 2, wherein the control of the tumor cells is by in vivo treatment by intraperitoneal administration of the tripeptide.
Claim 7
Dependent Claim
29 words
The method of claim 2, wherein the tumor cells are a member selected from a group consisting of leukemia L-1210 cells, MJY-alpha mammary tumor cells and B-16 melanoma cells.
Claim 8
Dependent Claim
20 words
The method of claim 2, wherein the tumor cells are controlled with a multiple therapeutically effective dose of the tripeptide.
Claim 9
Dependent Claim
24 words
The method of claim 7, wherein the multiple dose is administered at 10 mg per kg of subject weight on days 1 and 14.
Claim 10
Dependent Claim
27 words
The method of claim 7, wherein the multiple dose is administered at 5 mg per kg of subject weight on days 1, 4, 7, 21 and 42.
Claim 11
Independent Claim
44 words
A method of controlling tumor cells in vitro comprising administering to the tumor cells a therapeutically effective amount of a tripeptide compound, said tripeptide has members selected from a group consisting of: (1) 3-(p-fluorophenyl)-L-alanyl-3-[m-bis(2-chloroethyl)-aminophenyl]-L-alanyl-L-methionine (2) 3-[m-bis(2-chloroethyl)aminophenyl]-L-alanyl-3-(p-fluorophenyl)-L-alanyl-L-methionine (3) 3-(p-fluorophenyl)-L-alanyl-L-methionyl-3-[m-bis(2-chloroethyl)aminophenyl]-L-alanine (4) 3-[m-bis(2-chloroethyl)aminophenyl]-L-alanyl-L-methionyl-3-(p-fluorophenyl)-L-alanine (5) L-methionyl-3-(p-fluorophenyl)-L-alanyl-3-[m-bis(2-chloroethyl)aminophenyl]-L-alanine (6) L-methionyl-3-[m-bis(2-chloroethyl)aminophenyl]-L-alanyl-3-(p-fluorophenyl)-L-alanine.
Claim 12
Independent Claim
44 words
A method of controlling tumor cells in vitro comprising administering to the tumor cells a therapeutically effective amount of a tripeptide compound, said tripeptide has members selected from a group consisting of: (1) 3-(p-fluorophenyl)-L-alanyl-3-[m-bis(2-chloroethyl)-aminophenyl]-L-alanyl-L-methionine (2) 3-[m-bis(2-chloroethyl)aminophenyl]-L-alanyl-3-(p-fluorophenyl)-L-alanyl-L-methionine (3) 3-(p-fluorophenyl)-L-alanyl-L-methionyl-3-[m-bis(2-chloroethyl)aminophenyl]-L-alanine (4) 3-[m-bis(2-chloroethyl)aminophenyl]-L-alanyl-L-methionyl-3-(p-fluorophenyl)-L-alanine (5) L-methionyl-3-(p-fluorophenyl)-L-alanyl-3-[m-bis(2-chloroethyl)aminophenyl]-L-alanine (6) L-methionyl-3-[m-bis(2-chloroethyl)aminophenyl]-L-alanyl-3-(p-fluorophenyl)-L-alanine.
Claim 13
Dependent Claim
20 words
A method of controlling tumor cells as claimed in claim 10, wherein the tripeptide compound is 3-(p-fluorophenyl)-L-alanyl-3-[m-bis(2-chloroethyl)aminophenyl]-L-alanyl-L-methionine ethyl ester hydrochloride.
Claim 14
Independent Claim
94 words
A method of controlling tumor cells in vitro comprising: dissolving 10 mg of a tripeptide compound, said tripeptide compound is 3-(p-fluorophenyl)-L-alanyl-3-[m-bis(2-chloroethyl)aminophenyl]-L-alanyl-L-methionine ethyl ester hydrochloride, in a solution of 0.25 ml of N-N-dimethylacetamide, 0.25 ml of absolute ethanol and 0.5 ml of propylene glycol; diluting the dissolved tripeptide compound in an aqueous solution of 50% propylene glycol to a concentration of 1 to 2 mg per ml; and administering the tripeptide compound at concentrations ranging from 0.5 to 50 μg per ml of the tumor cells for 15 minutes to 24 hours at 37° C.
Claim 15
Independent Claim
94 words
A method of controlling tumor cells in vitro comprising: dissolving 10 mg of a tripeptide compound, said tripeptide compound is 3-(p-fluorophenyl)-L-alanyl-3-[m-bis(2-chloroethyl)aminophenyl]-L-alanyl-L-methionine ethyl ester hydrochloride, in a solution of 0.25 ml of N-N-dimethylacetamide, 0.25 ml of absolute ethanol and 0.5 ml of propylene glycol; diluting the dissolved tripeptide compound in an aqueous solution of 50% propylene glycol to a concentration of 1 to 2 mg per ml; and administering the tripeptide compound at concentrations ranging from 0.5 to 50 μg per ml of the tumor cells for 15 minutes to 24 hours at 37° C.
Claim 16
Dependent Claim
92 words
The method of claim 11, wherein 10 mg of the tripeptide is first dissolved in a solution of 0.25 ml of N,N-dimethylacetamide, 0.25 ml of pure ethanol, and 0.5 ml of propylene glycol; preparing the solution by further diluting the dissolved drug in an aqueous solution of 50% propylene glycol so that the stock solutions are concentrated in a range of 1 to 2 mg per ml; exposing the tumor cells to 0.5 to 50 μg of the tripeptide compound per ml of solvent for pulse exposure from 0.25 to 4 hr.
Claim 17
Dependent Claim
19 words
The method of claim 11, wherein the tumor cells are either MJY-alpha murine mammary cells or B-16 melanoma cells.
Claim 18
Dependent Claim
24 words
The method of claim 14, wherein the tumor cells are in a layer density of approximately 2×10 5 cells per sq. cm. of well.
Claim 19
Dependent Claim
26 words
The method of claim 11, wherein the tumor cells are a member selected from a group consisting of rabbit, marmoset, murine L-1210 and primary human leukemias.
Claim 20
Dependent Claim
17 words
The method of claim 16, wherein the tumor cells are at cell concentrations of 6-10×10 5 cells/ml.
References Cited (Backward Citations)
US4216208A
Cited
US4314999A
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1988-04-01 | 1988-10-01 | 1989-04-02 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1992-04-01 | 1992-10-01 | 1993-04-02 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 1996-04-01 | 1996-10-01 | 1997-04-02 | $7700.00 | Window Closed / Lapsed |